Treatment of Interstitial Lung Disease Associated Cough

Birring, Surinder S.; Irwin, Richard S.; Keogh, Karina A.; Ryu, Jay H.; Adams, Todd M.; Altman, Kenneth W.; Azoulay, Élie; Barker, Alan F.; Blackhall, Fiona; Boulet, Louis‐Philippe; Braman, Sidney S.; Brightling, Christopher E.; Callahan-Lyon, Priscilla; Chang, Anne B.; Davenport, Paul; Solh, Ali A. El; Escalante, Patricio; Field, Stephen K.; Fisher, Dina; French, Cynthia T.; Grant, Cameron; Harding, Susan M.; Gold, Philip M.; Harnden, Anthony; Hill, Adam T.; Kahrilas, Peter J.; Kavanagh, Joanne; Lai, Kefang; Lane, Andrew P.; Lim, Kaiser G.; Madison, J. Mark; Malesker, Mark A.; Mazzone, Stuart B.; McGarvey, Lorcan; Molasoitis, Alex; Moore, Aaron William; Murad, M. Hassan; Narasimhan, Mangala; Nguyen, Huong Q.; Newcombe, Peter; Oppenheimer, John; Restrepo, Marcos I.; Rosen, Mark J.; Rubin, Bruce K.; Singh, Sonal; Smith, Jennifer A.; Tarlo, Susan M.; Turmel, Julie; Vertigan, Anne E.; Wang, Gang; Weinberger, Miles

doi:10.1016/j.chest.2018.06.038

Cited by 56 publications

(61 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on the guidelines on cough associated ILD, there is a temporary lack of effective and safe drugs to relieve cough in IPF. [ 5 ] In previous meta-analyses of IPF treatment, most studies focused on the outcome index to prolong survival and delay the decline of lung function, the research on cough of IPF is blank. Compared with improving the value of lung function, relieving clinical symptoms, and improving patients QOL may be more valuable to patients with IPF.…”

Section: Discussionmentioning

confidence: 99%

“…In a CHEST guideline and expert panel report on cough associated interstitial lung disease (ILD) published in 2018, there are no effective drugs for the treatment of cough in IPF, so the treatment needs to be further explored at this stage. [ 5 ] In the past meta-analysis of IPF, most studies focused on survival time and changes in lung function, but the assessment of cough and QOL is still blank.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chinese herbal medicines for the treatment of cough in idiopathic pulmonary fibrosis

et al. 2020

View full text Add to dashboard Cite

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease with unknown etiology and hidden onset, which causes major health problems worldwide. Cough is a typical manifestation of IPF, which is usually characterized by cough without phlegm, and seriously affects the quality of life (QOL) of patients. At present, the treatment of IPF is mainly focused on prolonging survival time and improving lung function, such as pirfenidone, nintedanib, and N-acetylcysteine (NAC), but lack of effective measures to improve the QOL. Chinese herbal medicines (CHMs) is widely used in the clinical treatment of IPF. The adjuvant treatment of CHMs can effectively reduce the clinical symptoms of patients. Therefore, we designed this study to evaluate the role of CHMs in the treatment of cough in IPF. Method: This systematic review and meta-analysis will extract all randomized controlled trials (RCTs) related to the treatment of IPF from the following electronic database without date or language restrictions: PubMed, EMBASE, Cochrane CENTRAL, CNKI, VIP, CBM, and Wanfang database. The primary outcomes will be cough frequency and QOL, while secondary outcomes will include safety events. The methodologic quality of RCTs will be assessed using the Cochrane risk assessment tool. The I 2 test will be used to identify the extent of heterogeneity, and funnel plot analysis will be used to test the publication deviation (the number of studies included >10). We will use RevMan5.3 software for data synthesis and analysis. Result: This review evaluates the efficacy and safety of CHMs in combination therapy on cough frequency, the quality of life, adverse reactions and safety incidents in patients with IPF. Conclusion: This study protocol will be used to evaluate the efficacy and safety of CHMs in combination with conventional therapy in treatment of cough in IPF. OSF Registration DOI: 10.17605/OSF.IO/JKQYV.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Chinese herbal medicines for the treatment of cough in idiopathic pulmonary fibrosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…One study showed that inhaled corticosteroids may be effective in reducing cough in sarcoidosis, but two other small studies showed no effects of inhaled corticosteroids on cough in sarcoidosis [67][68][69]. Consequently, inhaled corticosteroids should not be routinely administered unless a trial demonstrates efficacy [70]. In the recent CHEST guideline, speech therapy is recommended for patients with ILD and refractory cough, however, this therapy has not been specifically evaluated in sarcoidosis [70].…”

Section: Complaints and Comorbiditiesmentioning

confidence: 99%

“…Consequently, inhaled corticosteroids should not be routinely administered unless a trial demonstrates efficacy [70]. In the recent CHEST guideline, speech therapy is recommended for patients with ILD and refractory cough, however, this therapy has not been specifically evaluated in sarcoidosis [70]. Vasoactive intestinal peptide (VIP) inhalation seemed to reduce cough in sarcoidosis in one small open clinical phase II study, but has never been investigated in a randomized setting [71].…”

Section: Complaints and Comorbiditiesmentioning

confidence: 99%

Comprehensive Care for Patients with Sarcoidosis

Moor

Kahlmann

Culver

et al. 2020

JCM

View full text Add to dashboard Cite

Sarcoidosis is a multisystem granulomatous disease, associated with significant morbidity and impaired quality of life. Treatment is aimed at recovering organ function, reducing symptom burden and improving quality of life. Because of the heterogeneity and variable disease course, a comprehensive, multidisciplinary approach to care is needed. Comprehensive care includes not only pharmacological interventions, but also supportive measures aimed at relieving symptoms and improving quality of life. The purpose of this review is to summarize the most recent knowledge regarding different aspects of care and propose a structured approach to sarcoidosis management.

show abstract

“…Eine erfolgreiche, erkrankungsspezifische Therapie ist häufig, aber nicht immer an der Reduktion der Hustensymptomatik erkennbar [53]. Bei refraktärem Husten im Rahmen einer ILD konnten in einer kürzlich publizierten Metanalyse keine spezifischen medikamentösen Maßnahmen gefunden werden, es wurden symptomatische Therapiemaßnahmen (Kapitel 9) empfohlen [56]. Für die Wirksamkeit der früher empfohlenen ICS (inhalatives Kortikosteroid)-Therapie bei der Sarkoidose fand sich keine Evidenz [56].…”

Section: Lungenparenchymerkrankungenunclassified

Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von erwachsenen Patienten mit Husten

et al. 2019

View full text Add to dashboard Cite

ZusammenfassungDie vorliegende 2019 S2k-Leitlinie der DGP wurde im Gegensatz zu den S3-Vorgänger-Leitlinien aus dem Jahre 2004 und 2010 für Pneumologen verfasst, für Allgemeinärzte liegt eine Leitlinie der Deutschen Gesellschaft für Allgemeinmedizin aus dem Jahre 2014 vor. Die Leitlinie enthält 48 im Konsensusverfahren abgestimmte Empfehlungen und 16 Statements, die im Hintergrundtext in den folgenden neun Kapiteln erläutert werden: Epidemiologie, Physiologie, Klassifizierung, akuter, subakuter bzw. chronischer Husten, Diagnostik und Therapie; dem chronischen idiopathischen Husten wurde ein Extra-Kapitel gewidmet. Weitere Schwerpunkte der Leitlinie sind die Physiologie des Hustens in Erwartung der Einführung neuer Medikamente sowie ausführliche Abhandlungen des Hustens, der durch Affektionen im Bereich der oberen Atemwege oder durch gastroösophagealen Reflux getriggert wird. Hier sollte die Leitlinie dem Pneumologen die zur Diagnostik und Therapie erforderlichen neuesten Kenntnisse aus den Nachbardisziplinen vermitteln. Die klinischen Kapiteln enthalten auch eine kurze Zusammenfassung, praktische Empfehlungen und jeweils ein eigenes Literaturverzeichnis. Drei neue, vereinfachte Algorithmen für den akuten, subakuten und chronischen Husten runden das Kapitel Diagnostik ab.

show abstract

Treatment of Interstitial Lung Disease Associated Cough

Abstract: The evidence supporting the management of chronic cough in ILD is limited. This guideline presents suggestions for managing and treating cough on the best available evidence, but future research is clearly needed.

Cited by 56 publications

References 59 publications

Chinese herbal medicines for the treatment of cough in idiopathic pulmonary fibrosis

Chinese herbal medicines for the treatment of cough in idiopathic pulmonary fibrosis

Comprehensive Care for Patients with Sarcoidosis

Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von erwachsenen Patienten mit Husten

Contact Info

Product

Resources

About